Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20689709 | 1.00 | SIGMAR1 (0.68) | SIGMAR1OPRK1HTTSMN1; SMN2MEN1 | |
| SCHEMBL20689717 | 1.00 | SIGMAR1 (0.68) | SIGMAR1OPRK1HTTSMN1; SMN2MEN1 | |
| SCHEMBL19498803 | 0.89 | OPRK1 (0.81) | SIGMAR1OPRK1HTTSMN1; SMN2MEN1 | |
| SCHEMBL22547154 | 0.88 | SIGMAR1 (0.62) | SIGMAR1OPRK1HTTSMN1; SMN2MEN1 | |
| SCHEMBL28873445 | 0.85 | SIGMAR1 (0.68) | SIGMAR1OPRK1HTTSMN1; SMN2MEN1 | |
| SCHEMBL11133210 | 0.84 | SIGMAR1 (0.68) | SIGMAR1MEN1KMT2A | |
| SCHEMBL11131206 | 0.82 | SIGMAR1 (0.65) | SIGMAR1OPRK1 | |
| SCHEMBL19498805 | 0.81 | SIGMAR1 (0.74) | SIGMAR1OPRK1 | |
| SCHEMBL9360922 | 0.81 | SIGMAR1 (1.00) | SIGMAR1OPRK1 | |
| SCHEMBL18435350 | 0.81 | SIGMAR1 (0.72) | SIGMAR1OPRK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223826-A1 | Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
| WO-2019023264-A1 | GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD)-MODULATING AGENTS AND METHODS OF TREATING G6PD DEFICIENCY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223826-A1 | Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency | G6PD, DPYD, G6PC1 | SIGMAR1 4859/4885OPRK1 3956/4885HTT 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.